IMEIK(SZ:300896)2022-03-07 16:00Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth rate of 30% in 2021 [8]. - The company's operating revenue for 2021 was ¥1,447,872,001.48, representing a 104.13% increase compared to ¥709,290,197.00 in 2020 [13]. - The net profit attributable to shareholders for 2021 was ¥957,798,548.01, a 117.81% increase from ¥439,748,783.82 in 2020 [13]. - The total profit for the year was 1,121.84 million CNY, with a year-on-year increase of 123.18% [25]. - The net profit reached 957.33 million CNY, reflecting a growth of 120.89% compared to the previous year [25]. - The company reported a net profit excluding non-recurring gains and losses of ¥914,421,058.03 for 2021, a 115.55% increase from ¥424,232,869.64 in 2020 [13]. - The company reported a basic earnings per share of ¥4.43, a decrease of 1.77% compared to ¥4.51 in 2020 [13]. - The company reported a significant increase in production and sales volumes across various product lines, driven by market expansion and improved product penetration [52]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth [134]. Market Position and Strategy - The company is focusing on expanding its market presence, particularly in the medical aesthetics sector, which is projected to grow by 15% annually [8]. - The company operates in the medical beauty industry, focusing on the research, manufacturing, and commercialization of Class III medical devices [19]. - The company holds a 27.2% market share in the sodium hyaluronate-based dermal filler market by sales volume, ranking first among all manufacturers in China [24]. - The company has seen a trend of domestic products replacing imported ones in the medical beauty sector, increasing its market share [19]. - The company is positioned in the midstream of the medical beauty value chain, benefiting from the growing consumer demand for beauty services in China [19]. - The company is actively pursuing strategic acquisitions to bolster its product offerings and market share [8]. - The company is focused on international market strategies and plans to issue H-shares to access international capital markets [98]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with discussions ongoing for two strategic targets [134]. Research and Development - The company has established several wholly-owned subsidiaries to enhance its research and development capabilities in biomedicine [6]. - The company invested 7.07% of its revenue in R&D, amounting to a 65.54% increase in R&D expenditure year-on-year [28]. - The company has accumulated 45 patents, including 25 invention patents, enhancing its competitive edge in the market [28]. - The company is conducting clinical trials for new products, including a modified hyaluronic acid gel and an injectable botulinum toxin, to enhance its product line and market position [61]. - The company aims to solidify its position in the skin filler market through new product developments and clinical trials [60]. - The company has initiated several R&D projects, including a 12,000 million RMB investment in the development of injectable type A botulinum toxin, expected to be completed by December 31, 2024 [84]. Corporate Governance and Compliance - The company has established a comprehensive governance structure, complying with relevant laws and regulations, ensuring effective internal management and control systems [103]. - The board of directors consists of 8 members, including 3 independent directors, ensuring a diverse range of expertise and compliance with legal requirements [106]. - The company has a transparent performance evaluation and incentive mechanism in place for senior management, promoting accountability and effective governance [108]. - The company emphasizes investor relations management, adhering to established protocols to maintain good communication and transparency with investors [113]. - The company operates independently from its controlling shareholders, with a complete and autonomous business operation system [114]. - The company has independent control over its assets, ensuring no guarantees or resource usage by related parties during the reporting period [115]. - The company has not engaged in any related party transactions that would compromise its financial independence [118]. - The company has maintained effective internal controls related to financial statements as of December 31, 2021 [164]. Social Responsibility and Sustainability - The company is committed to social and environmental responsibility, encouraging suppliers to obtain quality and safety certifications [170]. - The company donated 5 million RMB to support post-disaster reconstruction and mental health services in Henan after severe flooding in July 2021 [171]. - The management team emphasizes a commitment to sustainability, aiming for a 50% reduction in carbon footprint by 2025 [134]. - The company has implemented measures to ensure that emissions of pollutants comply with national and local environmental standards [166]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, through improved governance structures [168]. Employee Management and Development - The company has established a performance management system linked to a flexible compensation system to ensure employee interests are protected [151]. - The company plans to conduct 40-50 training sessions covering all employees, utilizing both online and offline platforms [152]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to CNY 17.534 million, including CNY 560,400 paid to independent directors [139]. - The company has a structured salary system for determining the remuneration of directors and senior management, approved by the shareholders' meeting and the board of directors [139]. - The employee composition includes 236 sales personnel, 117 technical staff, 88 production workers, 49 administrative staff, and 17 finance personnel [150]. Future Outlook - The company has provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB [134]. - New product launches are expected to contribute to growth, with three new skincare lines set to be introduced in Q2 2022 [134]. - Market expansion plans include entering two new international markets by the end of 2022, targeting a 30% increase in overseas sales [134]. - The company plans to enhance R&D investment and expand its product line in the field of biomedical materials and pharmaceuticals in 2022 [98].